Objective To operate a rapid health technology assessment for treatment of endometriosis with dienogest,providing evidence for clinical evaluation and decision-making.Methods The researches of dienogest on endometriosis were searched in Pubmed,Embase,CNKI,Wanfang and other databases.AMSTAR,OQAQ and CHEERS(2022)were used to evaluate the methodological quality of health economics,and the treatment of endometriosis with dienogest was comprehensive evaluated.Results The comprehensive evaluation results showed that dienogest had obvious advantages in preventing recurrence rate and improving pain after endometriosis surgery compared with expectant treatment,and was comparable to gonadotrophin releasing hormone analogue(GnRH-a).On safety evaluation,compared with other therapeutic drugs,dienogest had a higher risk of vaginal bleeding,and the risk of headache and weight gain also should be noted,while the risk of hot flashes,vaginal dryness and osteoporosis was relatively small.From perspective of medical insurance payment,dienogest was more cost-effective compared with GnRH-a,but had no advantage compared with combined oral contraceptives(COC).Conclusion Dienogest could be used as a long-term maintenance treatment after endometriosis surgery.However,compared with other treatments such as GnRH-a and COC,the efficacy,safety,and pharmacoeconomics of dienogest should be further explored.
关键词
地诺孕素/子宫内膜异位症/快速卫生技术评估/卫生经济学评价
Key words
dienogest/endometriosis/rapid health technology assessment/health economic evaluation
维普
万方数据